USPTO Rescinds Controversial Patent Rule Changes Proposed by Prior Administration

The USPTO also jointly filed a motion with GlaxoSmithKline to dismiss and vacate a federal district court decision in a lawsuit that sought to prevent the rules – which were viewed by many in the biotech industry as hindering IP protection – from taking effect.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.